BioSpace News Archive

Immix Biopharma, Inc. today announced dosing of an additional patient in its ongoing Phase 1b/2a IMX-110 monotherapy clinical trial.

Daxor Corporation today announces it will be presenting at the Society for Critical Care Medicine (SCCM) 2023 Critical Care Congress at the Moscone Center In San Francisco, CA from January 21 through the 24, 2023.

PDS Biotechnology Corporation today announced that its management will participate in a fireside chat at the B. Riley Securities 3rd Annual Oncology Conference being held virtually on January 18-19, 2023.

Jasper Therapeutics, Inc. today announced that new positive data for briquilimab (formerly known as JSP191), will be presented at the 2023 Tandem Meetings: Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR, taking place on February 15-19, 2023 in Orlando, Florida.

STRATA Skin Sciences, Inc. today announced a poster titled “Advancement of Personalized Photopneumatic Therapy for Rapid, Visible Improvement In Patients Mild to Moderate Acne” was accepted at the ODAC Dermatology, Aesthetic & Surgical Conference held at the JW Marriott Grande Lakes.

Equillium, Inc. today announced that an abstract was accepted for oral presentation at the Transplantation & Cellular Therapy Meetings of the American Society of Transplantation and Cellular Therapy, and the Center for International Blood & Marrow Transplant Research.

FSD Pharma Inc. is pleased to announce that its Board of Directors has authorized the repurchase under a normal course issuer bid (“NCIB”) of up to 1,925,210 of its Subordinate Class B Voting Shares (the “Subordinate Voting Shares”) from time to time over the next 12 months at prevailing market prices in order to allow the Company to use its excess cash reserves to strategically return value to shareholders.

Acasti Pharma Inc. today announced Jan D’alvise, CEO, will present and host one-on-one meetings with investors at the Sidoti January Virtual Investor Conference, taking place on January 18-19, 2023.

Neurocentria, Inc. has today announced that Dr. Thomas Südhof, Avram Goldstein Professor in Stanford University School of Medicine and an investigator of the Howard Hughes Medical Institute, has joined the company’s Scientific Advisory Board (SAB).

AnaptysBio, Inc. today announced that its Board of Directors has authorized a Stock Repurchase Plan under which the Company may repurchase up to $50,000,000 of the Company’s outstanding common stock, par value $0.001 per share.